Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily vs three-times-daily mesalazine granules in active ulcerative colitis
2004-001216-31Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Salcrozine in autoimmune colitis (2 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Clinical remission rate at final/withdrawal visit. Started Apr 2005; status: completed.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2004-001216-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001216-31.